Abstracts tagged "Abatacept"

Abstract Number: 884 • 2013 ACR/ARHP Annual Meeting
Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial
David Wofsy¹, Anca Askanase², Patricia C. Cagnoli³, W. Winn Chatham⁴, Gabriel Contreras⁵, Maria Dall'era⁶, Mary Anne Dooley⁷, Hilda Fragoso-Loyo⁸, David R. Karp⁹, Meenakshi Jolly¹⁰, Kenneth Kalunian¹¹, Diane L. Kamen¹², Iris Lee¹³, Marc C. Levesque¹⁴, S. Sam Lim¹⁵, Meggan Mackay¹⁶, Cesar Ramos-Remus¹⁷, Brad H. Rovin¹⁸, Tammy O. Utset¹⁹, Swamy Venuturupalli²⁰, Robert Winchester²¹, Linna Ding²², Wendy Gao²², Lynette Keyes-Elstein²³ and Patti Tosta²⁴, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²NYU School of Medicine, New York, NY, ³Int Med/Div of Rheum, University of Michigan Health, Ann Arbor, MI, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Miami, Miami, FL, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁹Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹⁰Rheumatology, Rush University Medical Center, Chicago, IL, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Nephrology, Temple University, Philadelphia, PA, ¹⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ¹⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ¹⁸Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ¹⁹Rheumatology, University of Chicago Medical Center, Chicago, IL, ²⁰Cedars-Sinai Medical Center, West Hollywood, CA, ²¹Dept of Medicine & Pathology, Columbia University, New York, NY, ²²NIAID, Bethesda, MD, ²³Rho Federal Systems, Inc., Chapel Hill, NC, ²⁴Immune Tolerance Network, San Francisco, CA
Background/Purpose: Studies in murine models for SLE have shown that CTLA4Ig can ameliorate murine lupus nephritis. Moreover, the combination of CTLA4Ig plus intravenous cyclophosphamide (IVC)…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting
Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber³ and J.a.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
Abstract Number: 723 • 2013 ACR/ARHP Annual Meeting
Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4⁺t Cells
Agapitos Patakas¹, Rui-Ru Ji², William Weir³, Sean Connolly², Steven G. Nadler², James M. Brewer⁴, Iain B. McInnes⁴ and Paul Garside⁴, ¹Institute of Infection, Immunology and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Immunology and Inflammation, Bristol Myers Squibb Co. Research and Development, Princeton, NJ, ³Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Absence of co-stimulation in the presence of TCR-stimulation has been proposed to induce tolerance via deletion or anergy. Abatacept is a CTLA-4-Ig molecule that…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 1679 • 2012 ACR/ARHP Annual Meeting
Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up
D. J. Lovell¹, N. Ruperto², R. Mouy², E. Paz², N. Rubio-Perez², C. A. Silva², C. Abud-Mendoza², R. Burgos-Vargas², V. Gerloni², J. a. Melo-Gomes³, C. Saad-Magalhaes², J. Chavez⁴, C. Huemer², A. Kivitz², F. Blanco², I. Foeldvari², Michael Hofer⁵, H. Huppertz², C. Job Deslandre², K. Minden², A. Flores Nunez⁶, A. J. Block⁷ and A. Martini², ¹Cincinnati Children's Hospital, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ⁴PRINTO, Genoa, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁶PRINTO, IRCCS Hospital para el Niño Poblano, Puebla, Mexico, ⁷Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: We previously reported the efficacy and safety of abatacept (ABA) in patients with juvenile idiopathic arthritis (JIA) in the AWAKEN trial1, during the 4-month…
Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Bohdan P. Harvey¹ and Zehra Kaymakcalan², ¹Biologics, Abbott Laboratories, Worcester, MA, ²Biologics, Abbott, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
Abstract Number: 1695 • 2012 ACR/ARHP Annual Meeting
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data
M. C. Genovese¹, M C. Hochberg², R. B. Cohen³, M. E. Weinblatt⁴, J. Kaine⁵, Edward Keystone⁶, P. Nash⁷, I. Delaet⁸ and R. Alten⁹, ¹Stanford University, Palo Alto, CA, ²Department of Medicine, University of Maryland, Baltimore, MD, ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁵Sarasota Arthritis Research Center, Sarasota, FL, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, ⁹Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment.…
Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting
An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)
Carol A. Langford¹, David Cuthbertson², Gary S. Hoffman³, Jeffrey Krischer⁴, Carol McAlear⁵, Paul A. Monach⁶, Philip Seo⁷, Ulrich Specks⁸, Steven R. Ytterberg⁹, Peter A. Merkel⁵ and for the Vasculitis Clinical Research Consortium⁵, ¹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁴University of South Florida, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁸Mayo Clinic, Rochester, MN, ⁹Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…
Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 1342 • 2012 ACR/ARHP Annual Meeting
Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael E. Weinblatt², Michael H. Schiff³, Dinesh Khanna⁴, Daniel Furst⁵ and Michael A. Maldonado⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology Division, University of Colorado, Denver, CO, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁶Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with pain, fatigue, disability and functional loss, which can significantly impact a patient's health-related quality of life (HRQoL). Patient-Reported…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…
Abstract Number: 1309 • 2012 ACR/ARHP Annual Meeting
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Alain G. Cantagrel³, Bernard Combe⁴, René-Marc Flipo⁵, Thierry Schaeverbeke⁶, Eric Houvenagel⁷, Philippe Gaudin⁸, Damien Loeuille⁹, Stephanie Rist¹⁰, Maxime Dougados¹¹, Jean Sibilia¹², Xavier Le Loet¹³, Christian Marcelli¹⁴, Thomas Bardin¹⁵, Isabelle Pane¹⁶, Elodie Perrodeau¹⁷, Gabriel Baron¹⁸ and Xavier Mariette¹⁹, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Rheumatology Department, Lille University Hospital, Lille, France, ⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁷Service de Rhumatologie, St Philibert Hospital, Lomme 59462, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ¹⁰Hospital University Orléans, France, ¹¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹²Rheumatology, CHU Hautepierre, Strasbourg, France, ¹³Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁴Rheumatology Department, Caen University Hospital, ¹⁵Rheumatology, Hôpital Lariboisière, Paris, France, ¹⁶Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁷Epidemiologist, Paris, France, ¹⁸Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Little data is available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis treated with abatacept (ABA) in daily…
Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
HC Leffers¹, Mikkel Østergaard¹, Bente Glintborg², Niels Steen Krogh³, Ulrik Tarp⁴, Tove Lorenzen⁵, Annette Hansen⁶, Michael Sejer Hansen⁷, Lene Dreyer², Martin S. Jakobsen² and Merete Lund Hetland⁸, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].